NAFLD vs NASH: What's the Difference and Why Should You Care?

You've been told you have a "fatty liver." But what does that actually mean? Is it just some extra fat that doesn't matter, or is it something you need to worry about? The answer depends on whether you have NAFLD (simple fat buildup) or NASH (fat with active inflammation and liver damage) — and that distinction can mean the difference between a manageable condition and one that quietly progresses to cirrhosis, liver failure, or even liver cancer.

In this guide, we'll explain exactly what NAFLD and NASH are, how they differ, the important name change to MASLD/MASH, who is most at risk, how each condition is diagnosed, and what you can do about it. We'll also explain why tracking your liver health from the earliest stages gives you the best chance of preventing serious damage.

⚡ Already Concerned About Your Liver?

Take the Liver Health Quiz for a quick risk check, or use our Liver Enzyme Checker to understand your ALT, AST, and other lab values. Both are free — no sign-up required.

First, the Name Change: NAFLD/NASH → MASLD/MASH

Before we dive in, you should know that the medical community officially renamed these conditions in 2023. A global panel of over 200 experts voted to replace the old names because they were considered stigmatizing (the word "fatty") and inaccurate (defining a disease by what it's not — "non-alcoholic" — rather than what it is).

The umbrella term is now Steatotic Liver Disease (SLD), which covers all causes of liver fat. A new category called MetALD was also created for patients with both metabolic risk factors and moderate alcohol consumption.

In this article, we'll use both old and new names since most patients are still more familiar with NAFLD/NASH, and much of the existing medical literature uses these terms. Both sets of names refer to the same conditions.

For a detailed overview of NAFLD/MASLD, visit our dedicated NAFLD condition page.

What Is NAFLD (MASLD)?

NAFLD — now called MASLD — is a condition where excess fat accumulates in the liver (a state called hepatic steatosis), in someone who has at least one metabolic risk factor such as obesity, diabetes, or high blood pressure. The term "steatosis" simply means fat buildup.

A healthy liver contains very little fat. When fat makes up more than 5% of the liver's weight, it's classified as steatosis. NAFLD/MASLD is the most common liver disease in the world, affecting an estimated 25–38% of the global adult population — that's over 2 billion people. In people with obesity, the rate is even higher: 60–90%. And in people with type 2 diabetes, it's approximately 60%.

The Two Forms of NAFLD/MASLD

NAFLD/MASLD exists on a spectrum with two main forms:

• Simple Steatosis (NAFL/MASL): Fat is present in the liver but there is no significant inflammation or liver cell damage. This is the milder, more common form. Most people with simple steatosis will never progress to serious liver disease. However, it's not entirely harmless — it's associated with increased cardiovascular risk and can progress in some patients.

• Steatohepatitis (NASH/MASH): Fat is present along with active inflammation and liver cell injury (a finding called "ballooning" on biopsy). This is the dangerous form — the one that can lead to fibrosis, cirrhosis, and liver cancer. Distinguishing between simple steatosis and NASH/MASH is the most important clinical question in fatty liver disease.

What Is NASH (MASH)?

NASH — now called MASH — is the inflammatory, progressive form of fatty liver disease. In NASH/MASH, the fat in your liver has triggered an immune response: your liver cells are inflamed, swollen ("ballooned"), and being damaged. Over time, this chronic injury leads to scar tissue formation (fibrosis), which can eventually progress to cirrhosis.

Approximately 7–35% of people with simple NAFLD/MASLD will progress to NASH/MASH. Once NASH is established, the risk of serious liver complications increases dramatically.

Why NASH/MASH Is Dangerous

NASH/MASH is dangerous because it is the gateway to irreversible liver damage:

• Fibrosis: Repeated inflammation causes scar tissue to replace healthy liver tissue. Fibrosis is staged from F0 (none) to F4 (cirrhosis).

• Cirrhosis: Advanced scarring that disrupts liver architecture and function. Once you reach this stage, complications like ascites, variceal bleeding, and hepatic encephalopathy can develop. Read more in our cirrhosis stages guide.

• Liver Cancer (HCC): NASH/MASH-related cirrhosis increases the risk of hepatocellular carcinoma. In fact, NASH is now one of the fastest-growing indications for liver transplant in both the US and Europe.

• Cardiovascular Disease: NASH/MASH patients have significantly higher rates of heart attack, stroke, and cardiovascular death — making it not just a liver disease, but a systemic metabolic condition.

Those with MASH face a 2.6% increased annual mortality risk compared to the general population.

NAFLD vs NASH: Side-by-Side Comparison

Who Is at Risk?

NAFLD/MASLD and NASH/MASH are deeply connected to metabolic syndrome — a cluster of conditions that together dramatically increase your health risks. You're at higher risk if you have:

• Overweight or obesity — especially central/abdominal obesity (visceral fat). Over 90% of people with severe obesity have some degree of fatty liver.

• Type 2 diabetes or insulin resistance — approximately 60% of people with type 2 diabetes have NAFLD/MASLD.

• High blood pressure (hypertension)

• High triglycerides or abnormal cholesterol (dyslipidemia)

• Polycystic ovary syndrome (PCOS)

• Sleep apnea

• Family history of fatty liver disease or cirrhosis

Growing Risk in Younger Adults

NAFLD/MASLD is no longer just a disease of middle-aged adults. Rising obesity rates, sedentary lifestyles, and processed food consumption mean that patients in their 20s and 30s are increasingly being diagnosed — many of them already showing signs of fibrosis. Pediatric NAFLD is also rising sharply. This makes early awareness and screening more important than ever.

Symptoms: The Silent Disease

One of the most concerning aspects of NAFLD and NASH is that most patients have no symptoms at all — even as significant damage accumulates. This is why NAFLD/MASLD has been called "the silent epidemic."

When symptoms do appear, they are typically vague and easily dismissed: fatigue and low energy, mild discomfort or fullness in the upper right abdomen, general malaise, and unexplained weight changes.

By the time more obvious symptoms develop — such as jaundice, abdominal swelling (ascites), or confusion — the disease has usually progressed to advanced fibrosis or cirrhosis.

This is why proactive monitoring of your liver enzymes and function is so important — it's often the only way to catch the disease before irreversible damage occurs. Learn what your lab results mean in our complete guide to liver function tests.

How Are NAFLD and NASH Diagnosed?

Blood Tests (Liver Function Tests)

Elevated ALT and AST levels on routine blood work are often the first clue that something is wrong with your liver. However, many patients with NAFLD — and even some with NASH — have completely normal liver enzymes. This means normal blood tests do not rule out fatty liver disease.

Use our Liver Enzyme Checker to understand what your ALT, AST, and other values mean, or upload your full lab report to LiverTracker's report tracker for automatic extraction and trend analysis.

Imaging

Ultrasound is the most common initial test — it can detect fat in the liver and is widely available. However, it cannot distinguish between simple steatosis and NASH, and may miss mild steatosis. FibroScan (transient elastography) is increasingly used because it measures both liver fat (CAP score) and liver stiffness (fibrosis) in a single, noninvasive test. Use our FibroScan Interpreter to understand your results, or log your FibroScan results in LiverTracker's FibroScan tracker to monitor changes over time.

Noninvasive Fibrosis Scores

Several scoring systems help estimate fibrosis severity without a biopsy: FIB-4 (uses age, ALT, AST, and platelet count), NFS (NAFLD Fibrosis Score), and FAST score (FibroScan-AST). These scores help your doctor decide whether you need further evaluation or referral to a hepatologist.

Liver Biopsy

A liver biopsy remains the gold standard for definitively diagnosing NASH/MASH and staging fibrosis. A small tissue sample is examined under a microscope for fat, inflammation, ballooning, and scarring. However, biopsy is invasive and not performed routinely — it's typically reserved for uncertain cases or when the degree of fibrosis will change management decisions.

The Progression Pathway: From Fat to Failure

Understanding the progression of fatty liver disease helps you understand why catching it early matters so much:

The key takeaway: the earlier you catch it, the more reversible it is. Once fibrosis advances to cirrhosis, the options narrow dramatically. This is why ongoing monitoring — not just a one-time check — is essential.

Treatment and Management

Lifestyle Changes (The Most Effective Treatment)

For both NAFLD and NASH, lifestyle intervention is the first-line treatment — and it is remarkably effective:

• Weight loss of 5–7% of body weight can significantly reduce liver fat (steatosis)

• Weight loss of 7–10% can resolve NASH inflammation and even reverse some fibrosis

• Exercise: At least 150 minutes per week of moderate aerobic activity (brisk walking, cycling, swimming) — exercise reduces liver fat independently of weight loss

• Diet: The Mediterranean diet has the strongest evidence for NAFLD/MASLD — emphasizing vegetables, fruits, whole grains, fish, olive oil, and nuts while limiting processed foods, added sugars, and saturated fats. Explore LiverTracker's liver-friendly recipe center for meal ideas, and use the food scanner to check any food's liver safety

• Avoid alcohol: Even moderate alcohol worsens liver fat and inflammation in NAFLD/MASLD patients

• Avoid fructose-heavy foods: High-fructose corn syrup and sugary drinks are strongly linked to fatty liver progression

Medications

Until recently, there were no FDA-approved drugs specifically for NASH/MASH. That changed significantly:

• Resmetirom (Rezdiffra): In March 2024, the FDA approved the first-ever drug specifically for NASH/MASH with moderate-to-advanced fibrosis (F2–F3). It is a thyroid hormone receptor agonist that reduces liver fat and inflammation. EU approval followed in August 2025.

• Semaglutide (Wegovy/Ozempic): In August 2025, the FDA expanded semaglutide's indication to include MASH with moderate-to-advanced fibrosis. In clinical trials, approximately 63% of patients achieved complete resolution of MASH, with significant weight loss (~13%) and fibrosis improvement.

• Pioglitazone and Vitamin E: Previously recommended by some guidelines for NASH patients without diabetes (Vitamin E) or with diabetes (pioglitazone), though with limitations and side effects.

Managing Metabolic Risk Factors

Since NAFLD/MASLD is fundamentally a metabolic disease, managing the underlying conditions is essential: controlling blood sugar (diabetes/insulin resistance), managing blood pressure, treating dyslipidemia with statins if appropriate (statins are safe in fatty liver disease), and treating sleep apnea if present.

Why Tracking Your Liver Health Matters — Even if You Feel Fine

Because NAFLD/MASLD and NASH/MASH are largely silent diseases, the only way to know what's happening inside your liver is through regular monitoring. Here's what tracking can tell you:

• Rising ALT/AST trends may signal progression from simple steatosis to NASH — even if individual values are still within the "normal" range. Our trend tracking feature makes this easy to visualize.

• FibroScan results over time show whether your liver stiffness (fibrosis) is stable, improving, or worsening. Track these with the FibroScan tracker.

• Imaging reports (ultrasound, CT, MRI) can be logged alongside your labs using imaging tracking for a complete picture.

• If NAFLD progresses to cirrhosis, your MELD score and Child-Pugh score become critical — both are calculated automatically when you upload labs to LiverTracker.

🚀 Start Monitoring Your Liver Today

1. Take the Liver Health Quiz for a quick risk assessment.

2. Use the Liver Enzyme Checker to understand your ALT and AST.

3. Use the FibroScan Interpreter if you've had a FibroScan.

4. Create your free LiverTracker account to upload lab reports, track trends, and get AI-powered health insights via the AI health chat.

Frequently Asked Questions

Is fatty liver disease serious?

Simple fatty liver (NAFL/MASL) by itself is generally not dangerous and is often reversible. However, it should be taken seriously as a warning sign — it indicates metabolic dysfunction and increases cardiovascular risk. If it progresses to NASH/MASH, it becomes a serious condition that can lead to cirrhosis, liver failure, and liver cancer.

How do I know if I have NAFLD or NASH?

You can't tell from symptoms alone — both are usually asymptomatic. Blood tests, imaging (especially FibroScan), and noninvasive fibrosis scores can help your doctor assess severity. The definitive distinction requires a liver biopsy, though newer noninvasive tests are increasingly reliable. Upload your labs to LiverTracker to track your values over time.

Can NAFLD be reversed?

Yes — simple steatosis is often reversible with sustained weight loss (5–7%), regular exercise, and dietary improvements. Even NASH/MASH can be reversed in many patients with 7–10% weight loss. New medications like resmetirom and semaglutide have also shown the ability to resolve NASH in clinical trials.

What foods should I avoid with fatty liver?

Limit or avoid sugary drinks and foods with high-fructose corn syrup, processed and fried foods, red and processed meats, refined carbohydrates (white bread, pastries), and alcohol. Use LiverTracker's food scanner to check any food's liver safety, and explore the recipe center for liver-friendly meal ideas.

Is NAFLD the same as MASLD?

Essentially yes — they refer to the same condition. MASLD is the updated name adopted in 2023 to better reflect the metabolic causes of the disease and to remove stigmatizing language. The diagnostic criteria overlap by approximately 99%. Similarly, NASH has been renamed to MASH.

Can I have NAFLD if I'm thin?

Yes — this is called "lean NAFLD" or "lean MASLD," and it affects up to 20% of normal-weight individuals. Insulin resistance, genetics, and visceral fat distribution (fat around organs, not just under the skin) play a role. Being thin does not protect you from fatty liver disease if you have metabolic risk factors.

Medical References & Sources

1. Rinella ME, Lazarus JV, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986. AASLD: AASLD MASLD Nomenclature

2. PMC. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. 2024. PMC Full Text

3. PMC. Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH. Gastroenterology & Hepatology. 2024. PMC Full Text

4. Wikipedia. Metabolic dysfunction–associated steatotic liver disease. Updated March 2026. Wikipedia (for FDA drug approval dates)

5. Labcorp. Nomenclature Change from NASH/NAFLD to MASH/MASLD. Labcorp Article

6. Kim WR, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021. PMC Full Text

Related Articles & Tools on LiverTracker

• NAFLD Condition Guide

• Complete Guide to Liver Function Tests

• Cirrhosis Stages Explained: From Compensated to Decompensated

• Living with Ascites: Causes, Symptoms, and How to Track Fluid Retention

• What Is MELD Score? A Patient-Friendly Guide

• Child-Pugh Score Explained

• Why Sodium Matters in Liver Disease

• Understanding the Liver Transplant Waiting List

• Liver Enzyme Checker Tool

• FibroScan Interpreter Tool

• Liver Health Quiz

• MELD Score Calculator

• Browse All Articles

🎯 Take Control of Your Liver Health Today

LiverTracker is the only platform built specifically for liver disease patients — from early-stage fatty liver to advanced cirrhosis. Upload lab reports, track trends, monitor FibroScan results, scan foods for liver safety, plan liver-friendly meals, get AI-powered health answers, and share reports with your doctor.

→ Take the Liver Health Quiz

→ Create Your Free Account

→ Download the iOS App

Medical Disclaimer: This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your hepatologist, gastroenterologist, or primary care physician for guidance specific to your condition. LiverTracker does not provide medical advice. For our complete disclaimer, visit livertracker.com/medical-disclaimer.